Health
Candidate monoclonal antibody shows hope as COVID-19 treatment – News-Medical.Net
Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome c…
Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The drug, called CPI-006, targets an immune signaling molecule called CD73 and activates CD73POS B cells, which subsequently promotes antibody production and differentiation into B cells.
In vitro, CPI-006 induce…
-
General18 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News18 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General20 hours agoPerth man charged after investigation into organised crime and tobacco store attacks
-
Noosa News17 hours agoMurray Watt claims Queensland will follow Sussan Ley and ditch net zero by 2050